The product will now be available for patients free of charge under the reimbursement scheme.
Researchers found no association between more potent cannabis and an increased risk of dependence or psychosis-like symptoms.
Only 8% products had concentrations within 10% of the advertised strength.
Catch up on some of the latest cannabis science.
The trial on non-cancer related chronic pain will recruit up to 5,000 patients.
The roll-out of cannabis reform in Malta is said to have brought a ‘significant transformation’ in the health and wellbeing of consumers, despite some concerns from...
Despite the approval of medicinal cannabis cultivation, the legal status of medical cannabis within Albania remains unclear.
Oxford Cannabinoid Technologies is expanding its research and development into oncology.
New research further supports the role of cannabinoids in the 'runner's high' experience.
Experts say giving GPs the right to prescribe cannabis would help drive down NHS waiting lists.